Pharmacologic: 5-HT3 antagonists
Prevention of acute and delayed nausea and vomiting caused by initial or repeat courses of moderate or highly emetogenic chemotherapy (intravenous). Prevention of acute nausea and vomiting caused by initial or repeat courses of moderately emetogenic chemotherapy (oral). Prevention of postoperative nausea and vomiting (PONV) for up to 24 hr after surgery (intravenous).
Blocks the effects of serotonin at receptor sites (selective antagonist) located in vagal nerve terminals and in the chemoreceptor trigger zones in the CNS. Therapeutic Effects: Decreased incidence and severity of nausea and vomiting following emetogenic chemotherapy or surgery.
Adverse Reactions/Side Effects
CNS: dizziness, headache. GI: constipation, diarrhea.
PHYSICAL THERAPY IMPLICATIONS
Examination and Evaluation
Monitor improvements in GI symptoms (decreased nausea and vomiting, increased appetite) to help document whether drug therapy is successful.
Assess dizziness that might affect gait, balance, and other functional activities (See Appendix C). Report balance problems and functional limitations to the physician and nursing staff, and caution the patient and family/caregivers to guard against falls and trauma.
Absorption: IV administration results in complete bioavailability; oral bioavailability = 97%.
Metabolism and Excretion: 50% metabolized; 40% excreted unchanged in urine.
|ROUTE ||ONSET ||PEAK ||DURATION |
|IV ||within 30 min ||unknown ||7 days |
|PO ||within 1 hr ||unknown ||7 days |
Contraindicated in: Hypersensitivity; cross-sensitivity with other 5-HT3 antagonists may occur; Lactation: Lactation.
Use Cautiously in: OB/Pedi: Safety not established.
Drug-Drug: None significant.
IV (Adults): Prevention of chemotherapy-induced nausea/vomiting—0.25 mg 30 min before start of chemotherapy; Prevention of PONV—0.075 mg given immediately before induction of anesthesia.
PO (Adults): 0.5 mg 1 hr before start of chemotherapy.
Solution for IV injection: 0.075 mg/1.5 mL, 0.25 mg/5 mL. Capsules: 0.5 mg.